About TwinStrand Biosciences
TwinStrand Biosciences is a company based in Seattle (United States) founded in 2015 by Mike Schmitt and Jesse Salk.. TwinStrand Biosciences has raised $84.02 million across 9 funding rounds from investors including ARE, HHS and Janus Henderson Investors. The company has 70 employees as of December 31, 2022. TwinStrand Biosciences offers products and services including Duplex Sequencing, AML Assay, Mutagenesis Assay, and Nitrosamine Testing. TwinStrand Biosciences operates in a competitive market with competitors including DNAnexus, Genomics, Seven Bridges Genomics, BC Platforms and Genomenon, among others.
- Headquarter Seattle, United States
- Employees 70 as on 31 Dec, 2022
- Founders Mike Schmitt, Jesse Salk
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Twinstrand Biosciences
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$84.02 M (USD)
in 9 rounds
-
Latest Funding Round
$10.28 M (USD), Series B
Jun 30, 2023
-
Investors
ARE
& 7 more
-
Employee Count
70
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of TwinStrand Biosciences
TwinStrand Biosciences offers a comprehensive portfolio of products and services, including Duplex Sequencing, AML Assay, Mutagenesis Assay, and Nitrosamine Testing. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
High-accuracy method for detecting rare DNA mutations in research.
Tool for measuring minimal residual disease in acute myeloid leukemia.
Assay to assess mutation frequencies and spectra in DNA samples.
Service for evaluating nitrosamine impurities in biological materials.
Unlock access to complete
Unlock access to complete
Funding Insights of TwinStrand Biosciences
TwinStrand Biosciences has successfully raised a total of $84.02M across 9 strategic funding rounds. The most recent funding activity was a Series B round of $10.28 million completed in June 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Series B — $10.3M
-
First Round
First Round
(24 Jun 2016)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2023 | Amount | Series B - TwinStrand Biosciences | Valuation |
investors |
|
| May, 2021 | Amount | Series B - TwinStrand Biosciences | Valuation | S32 | |
| Dec, 2019 | Amount | Series A - TwinStrand Biosciences | Valuation | Madrona Venture Group |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in TwinStrand Biosciences
TwinStrand Biosciences has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, HHS and Janus Henderson Investors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
Multiple sectors are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Venture capital investing in AI, biotech, and technology sectors, focusing on seed and early stages in Seattle and beyond.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by TwinStrand Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - TwinStrand Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Twinstrand Biosciences Comparisons
Competitors of TwinStrand Biosciences
TwinStrand Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as DNAnexus, Genomics, Seven Bridges Genomics, BC Platforms and Genomenon, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Cloud-based genome informatics and data management are provided.
|
|
| domain | founded_year | HQ Location |
Genomic risk assessment and prevention platform is provided.
|
|
| domain | founded_year | HQ Location |
Cloud-based platform to analyze, store, and act on genomic data.
|
|
| domain | founded_year | HQ Location |
Platforms for genomic data analysis and management are provided.
|
|
| domain | founded_year | HQ Location |
AI-based bioinformatics tools and genomic variants meta-database are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Twinstrand Biosciences
Frequently Asked Questions about TwinStrand Biosciences
When was TwinStrand Biosciences founded?
TwinStrand Biosciences was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Where is TwinStrand Biosciences located?
TwinStrand Biosciences is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Is TwinStrand Biosciences a funded company?
TwinStrand Biosciences is a funded company, having raised a total of $84.02M across 9 funding rounds to date. The company's 1st funding round was a Series A of $16.3M, raised on Jun 24, 2016.
How many employees does TwinStrand Biosciences have?
As of Dec 31, 2022, the latest employee count at TwinStrand Biosciences is 70.
What does TwinStrand Biosciences do?
TwinStrand Biosciences was founded in 2015 in Seattle, United States. Operations are centered in the biotechnology sector, where advanced DNA sequencing technologies are developed. Proprietary Duplex Sequencing is specialized in to identify genomic features that influence susceptibility to benzoapyrene-induced in vivo mutations. The companys work supports research into mutation detection and genomic analysis.
Who are the top competitors of TwinStrand Biosciences?
TwinStrand Biosciences's top competitors include DNAnexus, Eagle Genomics and Seven Bridges Genomics.
What products or services does TwinStrand Biosciences offer?
TwinStrand Biosciences offers Duplex Sequencing, AML Assay, Mutagenesis Assay, and Nitrosamine Testing.
Who are TwinStrand Biosciences's investors?
TwinStrand Biosciences has 8 investors. Key investors include ARE, HHS, Janus Henderson Investors, Soleus Capital, and Madrona.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.